Comprehensive Longevity Blood Panels Compared by Biomarker Count and Cost

Standard blood panels are built to catch disease once it's already there, not to catch the years of drift that lead to it. A CBC, a basic metabolic panel, a standard lipid panel: these flag problems after they've developed, while the markers longevity physicians actually lean on, ApoB, Lp(a), fasting insulin, hs-CRP, are typically nowhere on the requisition form.

That gap is visible most clearly in cardiovascular risk. ApoB counts the number of atherogenic particles moving through the bloodstream and driving plaque buildup in the arteries, which makes it a sharper predictor of cardiovascular risk than LDL cholesterol. Despite that, it's still not part of a routine draw. Lp(a) tells a similar story. It's driven heavily by genetics, and it can raise cardiovascular risk meaningfully even in people who look fit and healthy by every surface marker. The European Atherosclerosis Society backs checking it at least once in adulthood, yet most people never get it ordered.

Metabolic risk hides the same way. Fasting insulin and HOMA-IR can predict type 2 diabetes and cardiovascular disease years before a clinical diagnosis lands. HbA1c, which standard panels do include, only tells the story after blood sugar has already been running high for months. A person can look "fine" on paper for a decade while insulin resistance builds quietly underneath.

None of this means a normal lab result is meaningless. It means "normal" reflects a population range, and that range includes people who are already sick. Optimal and low-risk are different bars entirely, and standard panels were never built to clear them.

Once someone decides to test beyond the standard panel, they run into a market that's grown fast and crowded, full of services making very different promises about what they measure, how often, and what it costs. Sorting through that landscape is where the real decision-making starts.

Marker count and sticker price are the two numbers everyone compares first, and they're also the two numbers least likely to tell someone what they're actually paying for. A panel built around the lipid cluster (ApoB, Lp(a), triglycerides/HDL ratio), metabolic cluster (HbA1c, fasting insulin, HOMA-IR), and inflammation cluster (hs-CRP, homocysteine, ferritin) can deliver more actionable signal than a 160-marker panel padded with low-yield add-ons, because cluster logic matters more than raw count.

Cluster logic explains why a tightly designed 15–20 marker panel, smartly clustered following Lab2go's cluster-logic framing, can outperform a sprawling one. More rows on a lab report doesn't mean more insight. It can just mean more noise dressed up as thoroughness.

Marker count gets inflated another way too. Some services count algorithmically derived ratios, numbers calculated from other results, as if they were separate, directly measured biomarkers. One widely advertised "100+ biomarkers" claim actually includes derived ratios rather than all direct measurements, a distinction significant enough that it's now the subject of a pending lawsuit filed in January 2026. That biomarker count includes algorithmically derived ratios rather than all direct measurements, and it's the subject of a pending lawsuit filed by Function Health in January 2026 per AgelessLabs. That doesn't make the underlying test worthless, but the headline number needs a second look before anyone treats it as a direct measure of value.

Price runs into its own version of the same problem. Traditional lab billing pushes prices well above what the tests actually cost to run: a comparable 120-plus biomarker panel can run well over a thousand dollars through a hospital system, while direct-to-consumer options deliver the same markers for a fraction of that. So a high price doesn't necessarily buy better testing. It often just buys a more inefficient billing chain sitting between the patient and the lab.

A panel is worth paying for based on four things: which specific markers get directly measured, how often testing happens, whether the results arrive with real clinical interpretation attached, and whether the price reflects genuine lab cost or a billing-system markup. Keep those four in view, and the comparison that follows gets a lot easier to read.

The high-yield biomarker core every serious longevity panel should cover

Before lining up providers side by side, it helps to know what a strong panel actually contains, biologically, not just marketing copy. Think of it as a checklist built from evidence rather than branding.

Start with the lipid cluster. ApoB outperforms LDL as a predictor of cardiovascular events, backed by data from large cohort studies. Lp(a) belongs alongside it: genetically driven, rarely checked in routine care, and capable of raising cardiovascular risk even when everything else on a person's chart looks clean. The European Atherosclerosis Society's consensus supports at least one lifetime measurement. Round the cluster out with the triglycerides/HDL ratio, a standard lipid panel component that becomes far more informative once it's read next to ApoB rather than on its own.

The metabolic cluster tells the insulin resistance story earlier than most people expect. Fasting insulin flags trouble years before HbA1c catches up, and it's also tied to visceral fat accumulation, low-grade inflammation, and everyday fatigue. HbA1c still earns its place in the panel. It reflects average blood sugar over roughly the past two to three months, call it 8 to 12 weeks, but on its own it's a late-arriving signal. HOMA-IR, calculated from fasting insulin and glucose together, rounds out the cluster by capturing insulin resistance more completely than either marker alone can manage.

Inflammation deserves its own cluster too. hs-CRP has shown up as a predictor of cardiovascular events and all-cause mortality across large cohorts. Homocysteine ties into cardiovascular risk and B vitamin status, and ferritin, beyond its role as an iron storage marker, carries implications for both inflammation and energy levels.

Hormonal and nutritional markers layered on top make the picture more complete. Free and total testosterone, DHEA-S, and IGF-1 all decline with age, a pattern one longevity panel design explicitly builds around. A thyroid panel, TSH, free T3, free T4, shows up as a standard inclusion across comprehensive longevity panels. Vitamin D and B12 round out the core: deficiencies in both are common, and both tie directly into immune function, bone health, and mood.

Vitamin D (25-hydroxy) and B12 deficiencies are common and linked to immune function, bone health, and mood. A panel focused around this exact structure, priced transparently, shows that hitting this biological core doesn't require an enormous or expensive test menu. It requires the right markers, clustered correctly.

Six longevity testing services compared

The major direct-to-consumer longevity testing services in 2026 differ more deeply than price tags and marker counts suggest. Testing frequency, clinical depth, and the care model wrapped around the numbers separate these services more than any single headline figure does.

One entry-level option runs $199 per year for a single annual draw, advertising 100-plus biomarkers, or 150 once derived ratios get folded in. It covers a solid set of longevity fundamentals, including ApoB, a hormone panel spanning testosterone, estradiol, and DHEA-S, a thyroid panel (TSH, T3 Uptake, free T4), hs-CRP, Vitamin D, B12, ferritin, and complete metabolic and CBC panels. Lp(a) and the omega-3 index sit behind an add-on paywall rather than the base panel. This tier fits someone who wants a first comprehensive longevity baseline without committing to a large annual spend. Testing is available at Quest draw locations nationwide, though NY and NJ residents pay a higher regional rate instead of the standard price.

Further up the market sit services priced à la carte, as needed, with tiers ranging from a basic draw to a comprehensive executive panel and prices scaling substantially across tiers. Tiers range from a basic draw up through a comprehensive executive panel, and prices scale substantially as the marker count and clinical support climb with them. This model suits someone who wants a specific, targeted panel, say, for hormone optimization or a one-off deep dive, rather than a recurring annual subscription.

At the flexible end sits à la carte testing with unlimited draws and any combination of markers a person wants to order. Nothing forces a fixed panel structure here. A custom longevity-relevant combination, Lp(a), fasting insulin, hs-CRP, and the rest of the core cluster, can get assembled at a relatively modest cost. The tradeoff is that nothing gets curated automatically. Building the right panel takes some outside knowledge of which markers actually matter, the exact knowledge this piece has been laying out.

Other services in this market land at different points along the same three axes: price, draw frequency, and how much clinical guidance comes bundled with the results. Some prioritize frequent retesting for people actively training or adjusting a protocol. Others build around a single annual snapshot paired with a heavier interpretive layer. None of these models is objectively "best." The right one depends on how often someone wants to retest, how much interpretation they need attached to the numbers, and whether they're comfortable assembling their own panel from an à la carte menu or would rather have one built for them. Anyone comparing options directly should confirm current pricing, draw frequency, and marker counts on each provider's own site before deciding. Some of these figures move year to year, and a few sources report slightly different numbers for the same service.

Where transparent, membership-based testing fits in this landscape

Step back across all six models above: most of them share the same distortion this piece opened by pointing out, that price tends to track positioning and billing structure, not the actual cost of running the test. A membership model that charges at-cost for testing, and makes its money from the membership itself rather than from test volume, sits on a structurally different incentive. There's no financial upside to piling on markers a member doesn't need. If anything, the incentive runs the other way: recommend fewer tests when the data says fewer tests are enough.

An analysis pointed to a platform running exactly this model: 100-plus biomarkers analyzed for a transparent per-test fee, biological age calculated directly from blood data, personalized reference ranges adjusted for ethnicity and lifestyle rather than generic population averages, and a 1:1 virtual clinician consultation included in the price. That combination landed among the strongest price-to-biomarker ratios found anywhere in the market.

A few features set this category apart from the rest of the comparison. Biological age gets calculated straight from blood biomarkers, not estimated from a wearable device. Reference ranges shift based on ethnicity, lifestyle, and individual goals instead of relying on one generic population range for everyone. Each member gets a 1:1 virtual clinician consult built into the service, plus ongoing AI-assisted messaging to ask questions between full testing cycles. Results typically land in about five business days, with draws available at Quest or LabCorp locations across every state where the service operates.

That's the throughline connecting every section here. Marker count alone doesn't determine value, and neither does sticker price. A genuinely useful longevity panel carries markers with real predictive power, ApoB, Lp(a), fasting insulin, hs-CRP, and the rest of that core cluster, priced to reflect what the testing actually costs to run. Held up against that standard, transparent at-cost pricing paired with real clinical interpretation is central to this market. It's the model the rest of the comparison keeps circling back to.